The EBP1/PA2G4 antibody targets the ErbB3-binding protein 1 (EBP1), also known as proliferation-associated protein 2G4 (PA2G4), a multifunctional protein involved in cell proliferation, differentiation, and apoptosis. EBP1 interacts with the ErbB3 receptor tyrosine kinase and modulates downstream signaling pathways, including RAS/ERK and PI3K/AKT, influencing cellular growth and survival. It exhibits dual roles in cancer, acting as either a tumor suppressor or promoter depending on cellular context, and is implicated in breast, prostate, and other cancers. EBP1 also participates in ribosome biogenesis, RNA metabolism, and transcriptional regulation, interacting with nuclear receptors and chromatin-modifying complexes.
Structurally, EBP1 has two isoforms, p48 and p42. generated by alternative splicing. The p42 isoform promotes cell survival, while p48 induces differentiation. EBP1/PA2G4 antibodies are essential tools for detecting these isoforms in research, aiding in studies of their distinct functions. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions in both normal and pathological states. Commercial antibodies are typically raised in rabbits or mice, with clones like C1 or E1 validated for specificity. Research on EBP1/PA2G4 antibodies continues to explore its role in cancer progression, viral pathogenesis (e.g., interactions with EBV or HPV proteins), and neurodegenerative disorders, highlighting its therapeutic and diagnostic potential.